{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:38:57Z","timestamp":1793551137127,"version":"4.5.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,6]]},"DOI":"10.1093\/jnci\/djr160","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T04:46:13Z","timestamp":1306212373000},"page":"1007-1017","source":"Crossref","is-referenced-by-count":212,"title":["Novel Proteasome Inhibitors to Overcome Bortezomib Resistance"],"prefix":"10.1093","volume":"103","author":[{"given":"Amy M.","family":"Ruschak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Slassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"issue":"6","key":"key\n\t\t\t\t20170702055447_bib1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S1097-2765(03)00452-0","article-title":"The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1","volume":"12","author":"Walden","year":"2003","journal-title":"Mol Cell."},{"issue":"6929","key":"key\n\t\t\t\t20170702055447_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature01456","article-title":"Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8","volume":"422","author":"Walden","year":"2003","journal-title":"Nature."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.emboj.7600552","article-title":"Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1","volume":"24","author":"Lois","year":"2005","journal-title":"Embo J."},{"issue":"13","key":"key\n\t\t\t\t20170702055447_bib4","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.1016\/S0021-9258(20)82050-X","article-title":"Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown","volume":"258","author":"Hershko","year":"1983","journal-title":"J Biol Chem."},{"issue":"4898","key":"key\n\t\t\t\t20170702055447_bib5","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1126\/science.2538923","article-title":"A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein","volume":"243","author":"Chau","year":"1989","journal-title":"Science."},{"issue":"7148","key":"key\n\t\t\t\t20170702055447_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nature05902","article-title":"Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging","volume":"447","author":"Jin","year":"2007","journal-title":"Nature."},{"issue":"26","key":"key\n\t\t\t\t20170702055447_bib7","doi-asserted-by":"crossref","first-page":"13258","DOI":"10.1016\/S0021-9258(18)37699-3","article-title":"The resolution and characterization of putative ubiquitin carrier protein isozymes from rabbit reticulocytes","volume":"263","author":"Haas","year":"1988","journal-title":"J Biol Chem."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1104\/pp.105.067983","article-title":"Genome analysis and functional characterization of the E2 and RING-type E3 ligase ubiquitination enzymes of Arabidopsis","volume":"139","author":"Kraft","year":"2005","journal-title":"Plant Physiol."},{"issue":"2","key":"key\n\t\t\t\t20170702055447_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1097-2765(00)80020-9","article-title":"A function for monoubiquitination in the internalization of a G protein-coupled receptor","volume":"1","author":"Terrell","year":"1998","journal-title":"Mol Cell."},{"issue":"6879","key":"key\n\t\t\t\t20170702055447_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/416451a","article-title":"A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins","volume":"416","author":"Polo","year":"2002","journal-title":"Nature."},{"issue":"1","key":"key\n\t\t\t\t20170702055447_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molcel.2007.11.002","article-title":"Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation","volume":"29","author":"Zhou","year":"2008","journal-title":"Mol Cell."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","article-title":"The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway","volume":"17","author":"Nijman","year":"2005","journal-title":"Mol Cell."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrm1908","article-title":"Regulation of DNA repair by ubiquitylation","volume":"7","author":"Huang","year":"2006","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ncb1378","article-title":"Regulation of monoubiquitinated PCNA by DUB autocleavage","volume":"8","author":"Huang","year":"2006","journal-title":"Nat Cell Biol."},{"issue":"65","key":"key\n\t\t\t\t20170702055447_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes","volume":"65","author":"Coux","year":"1996","journal-title":"Annu Rev Biochem."},{"issue":"6","key":"key\n\t\t\t\t20170702055447_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80929-0","article-title":"The proteasome: paradigm of a self-compartmentalization protease","volume":"92","author":"Baumeister","year":"1998","journal-title":"Cell."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0092-8674(00)81603-7","article-title":"A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3","volume":"94","author":"Glickman","year":"1998","journal-title":"Cell."},{"issue":"5210","key":"key\n\t\t\t\t20170702055447_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"Lowe","year":"1995","journal-title":"Science."},{"issue":"6624","key":"key\n\t\t\t\t20170702055447_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature."},{"issue":"11","key":"key\n\t\t\t\t20170702055447_bib20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat Struct Biol."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tcb.2010.03.007","article-title":"Assembly, structure, and function of the 26S proteasome","volume":"20","author":"Bedford","year":"2010","journal-title":"Trends Cell Biol."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","article-title":"The structure of the mammalian 20S proteasome at 2.75 A resolution","volume":"10","author":"Unno","year":"2002","journal-title":"Structure."},{"issue":"40","key":"key\n\t\t\t\t20170702055447_bib23","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"J Biol Chem."},{"issue":"6","key":"key\n\t\t\t\t20170702055447_bib24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0092-8674(00)80171-3","article-title":"Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly","volume":"86","author":"Chen","year":"1996","journal-title":"Cell."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1006\/jmbi.1998.1818","article-title":"Conformational constraints for protein self-cleavage in the proteasome","volume":"279","author":"Ditzel","year":"1998","journal-title":"J Mol Biol."},{"issue":"21","key":"key\n\t\t\t\t20170702055447_bib26","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1073\/pnas.95.21.12504","article-title":"Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1","volume":"95","author":"Nussbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"40","key":"key\n\t\t\t\t20170702055447_bib27","doi-asserted-by":"crossref","first-page":"25637","DOI":"10.1074\/jbc.273.40.25637","article-title":"Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants","volume":"273","author":"Dick","year":"1998","journal-title":"J Biol Chem."},{"issue":"14","key":"key\n\t\t\t\t20170702055447_bib28","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1073\/pnas.94.14.7156","article-title":"Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation","volume":"94","author":"Arendt","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"key\n\t\t\t\t20170702055447_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.12.020","article-title":"Proteasome activators","volume":"41","author":"Stadtmueller","year":"2011","journal-title":"Mol Cell."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib30","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/emboj.2009.382","article-title":"Interactions of PAN\u2019s C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome-ATPase interactions","volume":"29","author":"Yu","year":"2010","journal-title":"Embo J."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib31","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1074\/jbc.273.4.1982","article-title":"Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes","volume":"273","author":"Kisselev","year":"1998","journal-title":"J Biol Chem."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib32","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1074\/jbc.272.3.1791","article-title":"Processive degradation of proteins and other catalytic properties of the proteasome from Thermoplasma acidophilum","volume":"272","author":"Akopian","year":"1997","journal-title":"J Biol Chem."},{"issue":"20","key":"key\n\t\t\t\t20170702055447_bib33","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1073\/pnas.96.20.10976","article-title":"The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study","volume":"96","author":"Groll","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6555","key":"key\n\t\t\t\t20170702055447_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/378416a0","article-title":"A protein catalytic framework with an N-terminal nucleophile is capable of self-activation","volume":"378","author":"Brannigan","year":"1995","journal-title":"Nature."},{"issue":"6342","key":"key\n\t\t\t\t20170702055447_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/353357a0","article-title":"A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC","volume":"353","author":"Glynne","year":"1991","journal-title":"Nature."},{"issue":"6345","key":"key\n\t\t\t\t20170702055447_bib36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/353664a0","article-title":"Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene","volume":"353","author":"Martinez","year":"1991","journal-title":"Nature."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib37","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.4049\/jimmunol.156.7.2361","article-title":"Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit","volume":"156","author":"Nandi","year":"1996","journal-title":"J Immunol."},{"issue":"17","key":"key\n\t\t\t\t20170702055447_bib38","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res."},{"issue":"19","key":"key\n\t\t\t\t20170702055447_bib39","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/cncr.23224","article-title":"Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits","volume":"112","author":"Busse","year":"2008","journal-title":"Cancer."},{"issue":"16","key":"key\n\t\t\t\t20170702055447_bib41","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood."},{"issue":"26","key":"key\n\t\t\t\t20170702055447_bib42","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med."},{"issue":"30","key":"key\n\t\t\t\t20170702055447_bib43","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","article-title":"Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition","volume":"67","author":"Meister","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib45","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1158\/0008-5472.CAN-05-2321","article-title":"Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis","volume":"66","author":"Bazzaro","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib46","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure."},{"issue":"15","key":"key\n\t\t\t\t20170702055447_bib49","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1021\/ja058320b","article-title":"Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding","volume":"128","author":"Groll","year":"2006","journal-title":"J Am Chem Soc."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr0502504","article-title":"20S proteasome and its inhibitors: crystallographic knowledge for drug development","volume":"107","author":"Borissenko","year":"2007","journal-title":"Chem Rev."},{"issue":"12","key":"key\n\t\t\t\t20170702055447_bib51","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1535-7163.MCT-06-0185","article-title":"Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib","volume":"5","author":"Williamson","year":"2006","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell."},{"issue":"24","key":"key\n\t\t\t\t20170702055447_bib53","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med."},{"issue":"9","key":"key\n\t\t\t\t20170702055447_bib54","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood."},{"issue":"34","key":"key\n\t\t\t\t20170702055447_bib56","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib57","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/leu.2010.116","article-title":"Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study","volume":"24","author":"Kumar","year":"2010","journal-title":"Leukemia."},{"issue":"10","key":"key\n\t\t\t\t20170702055447_bib58","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"8","key":"key\n\t\t\t\t20170702055447_bib59","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/leu.2010.129","article-title":"Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial","volume":"24","author":"Dispenzieri","year":"2010","journal-title":"Leukemia."},{"issue":"6","key":"key\n\t\t\t\t20170702055447_bib60","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood."},{"issue":"7","key":"key\n\t\t\t\t20170702055447_bib61","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","article-title":"Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line","volume":"37","author":"Lu","year":"2009","journal-title":"Exp Hematol."},{"issue":"14","key":"key\n\t\t\t\t20170702055447_bib62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jnci\/djq198","article-title":"Effect of noncompetitive proteasome inhibition on bortezomib resistance","volume":"102","author":"Li","year":"2010","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"key\n\t\t\t\t20170702055447_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.leukres.2005.06.014","article-title":"No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib","volume":"30","author":"Politou","year":"2006","journal-title":"Leuk Res."},{"key":"key\n\t\t\t\t20170702055447_bib64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1476-4598-9-110","article-title":"Characterization of bortezomib-adapted I-45 mesothelioma cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol Cancer."},{"issue":"19","key":"key\n\t\t\t\t20170702055447_bib65","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib66","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib67","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Sanchez","year":"2010","journal-title":"Br J Haematol."},{"issue":"5","key":"key\n\t\t\t\t20170702055447_bib68","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Piva","year":"2008","journal-title":"Blood."},{"issue":"9","key":"key\n\t\t\t\t20170702055447_bib69","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood."},{"issue":"13","key":"key\n\t\t\t\t20170702055447_bib70","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"issue":"22","key":"key\n\t\t\t\t20170702055447_bib71","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin Cancer Res."},{"key":"key\n\t\t\t\t20170702055447_bib72","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","author":"Martin"},{"issue":"9","key":"key\n\t\t\t\t20170702055447_bib73","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem."},{"issue":"23","key":"key\n\t\t\t\t20170702055447_bib74","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1182\/blood-2010-04-276626","article-title":"A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma","volume":"116","author":"Chauhan","year":"2010","journal-title":"Blood."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora","volume":"42","author":"Feling","year":"2003","journal-title":"Angew Chem Int Ed Engl."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib76","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2010.08144.x","article-title":"Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model","volume":"149","author":"Singh","year":"2010","journal-title":"Br J Haematol."},{"issue":"1","key":"key\n\t\t\t\t20170702055447_bib77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2006-03-013128","article-title":"NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells","volume":"110","author":"Miller","year":"2007","journal-title":"Blood."},{"key":"key\n\t\t\t\t20170702055447_bib78","doi-asserted-by":"crossref","article-title":"Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma","author":"Richardson","DOI":"10.1182\/blood.V112.11.2770.2770"},{"issue":"15","key":"key\n\t\t\t\t20170702055447_bib79","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1073\/pnas.92.15.7085","article-title":"Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39","volume":"92","author":"Gudmundsson","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"key\n\t\t\t\t20170702055447_bib80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/71527","article-title":"PR39, a peptide regulator of angiogenesis","volume":"6","author":"Li","year":"2000","journal-title":"Nat Med."},{"issue":"29","key":"key\n\t\t\t\t20170702055447_bib81","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1021\/bi034784f","article-title":"Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity","volume":"42","author":"Gaczynska","year":"2003","journal-title":"Biochemistry."},{"issue":"26","key":"key\n\t\t\t\t20170702055447_bib82","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.1021\/bi8005913","article-title":"TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors","volume":"47","author":"Sprangers","year":"2008","journal-title":"Biochemistry."},{"issue":"7688","key":"key\n\t\t\t\t20170702055447_bib83","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(71)80056-9","article-title":"Prophylactic value of clioquinol against travellers\u2019 diarrhoea","volume":"1","author":"Richards","year":"1971","journal-title":"Lancet."},{"issue":"7614","key":"key\n\t\t\t\t20170702055447_bib84","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(69)90037-3","article-title":"Trial of clioquinol in cholera","volume":"2","author":"Woodward","year":"1969","journal-title":"Lancet."},{"issue":"7796","key":"key\n\t\t\t\t20170702055447_bib85","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(73)90004-4","article-title":"Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey","volume":"1","author":"Nakae","year":"1973","journal-title":"Lancet."},{"issue":"1\u20132","key":"key\n\t\t\t\t20170702055447_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2003.11.007","article-title":"Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban","volume":"218","author":"Konagaya","year":"2004","journal-title":"J Neurol Sci."},{"issue":"3","key":"key\n\t\t\t\t20170702055447_bib87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2008.232","article-title":"Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma","volume":"23","author":"Mao","year":"2009","journal-title":"Leukemia."},{"issue":"8","key":"key\n\t\t\t\t20170702055447_bib88","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/0008-5472.CAN-04-3577","article-title":"Anticancer activity of the antibiotic clioquinol","volume":"65","author":"Ding","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib89","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-06-3546","article-title":"Clioquinol, a therapeutic agent for Alzheimer\u2019s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20170702055447_bib90","doi-asserted-by":"crossref","first-page":"R897","DOI":"10.1186\/bcr1322","article-title":"Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells","volume":"7","author":"Daniel","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"11","key":"key\n\t\t\t\t20170702055447_bib91","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/iub.253","article-title":"Metal ionophores\u2014an emerging class of anticancer drugs","volume":"61","author":"Ding","year":"2009","journal-title":"IUBMB Life."},{"issue":"13","key":"key\n\t\t\t\t20170702055447_bib92","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1088\/0031-9155\/47\/13\/310","article-title":"Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study","volume":"47","author":"Geraki","year":"2002","journal-title":"Phys Med Biol."},{"issue":"4","key":"key\n\t\t\t\t20170702055447_bib93","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/1097-0142(19890215)63:4<726::AID-CNCR2820630421>3.0.CO;2-P","article-title":"Use of the copper\/zinc ratio in the diagnosis of lung cancer","volume":"63","author":"Diez","year":"1989","journal-title":"Cancer."},{"issue":"2","key":"key\n\t\t\t\t20170702055447_bib94","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01324697","article-title":"Quantitative analysis of copper, zinc and copper\/zinc ratio in selected human brain tumors","volume":"16","author":"Yoshida","year":"1993","journal-title":"J Neurooncol."},{"issue":"11","key":"key\n\t\t\t\t20170702055447_bib95","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","article-title":"The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma","volume":"115","author":"Xu","year":"2010","journal-title":"Blood."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/103\/13\/1007\/17984943\/djr160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:26:54Z","timestamp":1712449614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djr160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":95,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2011,5,23]]},"published-print":{"date-parts":[[2011,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djr160","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,23]]}}}